Showing results (11-20 of 205) with videos related to
Sort By:
Pageof 21
Current Opinion in Investigational Drugs (London, England : 2000)|January 15, 2005
TG-4010 TransgeneSeth Cohen, Howard L KaufmanCurrent Opinion in Molecular Therapeutics|August 27, 2005
Gene therapy with poxvirus vectorsDorota Moroziewicz, Howard L KaufmanExpert Opinion on Drug Safety|September 21, 2017
High-dose interleukin-2 (IL-2) for the treatment of melanoma: safety considerations and future directionsStephen Marabondo, Howard L KaufmanSeminars in Cancer Biology|March 6, 2004
Local delivery of poxvirus vaccines for melanomaHeidi Hörig, Howard L KaufmanMethods in Molecular Biology (Clifton, N.J.)|July 2, 2009
Gene therapy for antitumor vaccinationSeunghee Kim-Schulze, Howard L KaufmanFuture Oncology (London, England)|June 10, 2010
OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanomaHoward L Kaufman, Steven D BinesThe Journal of Clinical Investigation|March 3, 2004
Immune system versus tumor: shifting the balance in favor of DCs and effective immunityHoward L Kaufman, Mary L DisisClinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 1, 2016
Molecular Pathways: Mechanism of Action for Talimogene Laherparepvec, a New Oncolytic Virus ImmunotherapyFrederick J Kohlhapp, Howard L KaufmanFuture Oncology (London, England)|October 5, 2017
Avelumab and other recent advances in Merkel cell carcinomaPraveen K Bommareddy, Howard L KaufmanPageof 21